

This article was downloaded by:

On: 26 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



## Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597286>

### Unusual Lability of 5'-*O*-*tert*-Butyldimethylsilyl Group On 4''-Acyl TSAO Derivatives

Sonia de Castro<sup>a</sup>; María-Jesús Pérez-Pérez<sup>a</sup>; Esther Lobatón<sup>a</sup>; Erik De Clercq<sup>b</sup>; Jan Balzarini<sup>b</sup>; María-José Camarasa<sup>a</sup>; Sonsoles Velázquez<sup>a</sup>

<sup>a</sup> Instituto de Química Médica (C.S.I.C.), Madrid, Spain <sup>b</sup> Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium

Online publication date: 09 August 2003

**To cite this Article** de Castro, Sonia , Pérez-Pérez, María-Jesús , Lobatón, Esther , De Clercq, Erik , Balzarini, Jan , Camarasa, María-José and Velázquez, Sonsoles(2003) 'Unusual Lability of 5'-*O*-*tert*-Butyldimethylsilyl Group On 4''-Acyl TSAO Derivatives', *Nucleosides, Nucleotides and Nucleic Acids*, 22: 5, 959 — 961

**To link to this Article:** DOI: 10.1081/NCN-120022695

**URL:** <http://dx.doi.org/10.1081/NCN-120022695>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

## Unusual Lability of 5'-*O*-*tert*-Butyldimethylsilyl Group On 4''-Acyl TSAO Derivatives<sup>†</sup>

Sonia de Castro,<sup>1</sup> María-Jesús Pérez-Pérez,<sup>1</sup> Esther Lobatón,<sup>1</sup>  
Erik De Clercq,<sup>2</sup> Jan Balzarini,<sup>2</sup> María-José Camarasa,<sup>1</sup>  
and Sonsoles Velázquez<sup>1,\*</sup>

<sup>1</sup>Instituto de Química Médica (C.S.I.C.), Madrid, Spain

<sup>2</sup>Rega Institute for Medical Research, Katholieke Universiteit Leuven,  
Leuven, Belgium

TSAO-m<sup>3</sup>T (**1**) is the prototype compound of a unique family of HIV-1-specific non-nucleoside reverse transcriptase inhibitors (NNRTIs) that seems to interact at the interface between the p51 and p66 reverse transcriptase (RT) subunits.<sup>[1,2]</sup> As part of our program on the synthesis of a “second generation” of TSAO derivatives directed against TSAO-resistant HIV-1 strains (GluB138Lys), we focused on the preparation of TSAO derivatives that contain carbonyl groups at the 4'' position of the spiro moiety, that may form H-bonds with the NH<sub>2</sub> group of Lys 138 of the mutant HIV-1 RT. We found that compound **2** (Fig. 1) bearing an oxalyl moiety at the 4'' position showed an unusual lability of the 5'-*O*-*tert*-butyldimethylsilyl group (TBDMS) in DMSO solution. This facile desilylation was not observed, previously, with the more than 500 TSAO derivatives prepared so far.<sup>[2]</sup>

In this communication we investigated the nature of this unexpectedly facile desilylation. Several modifications on the TSAO-oxalyl derivative **2**, following standard synthetic procedures, were carried out. Thus, introduction of different

<sup>†</sup>This paper is dedicated to the memory of Dr. Manfred Stud.

\*Correspondence: Sonsoles Velázquez, Instituto de Química Médica (C.S.I.C.), C/Juan de la Cierva, 2, E-28006, Madrid, Spain; Fax: +34 1 564 4853; E-mail: iqmsv29@iqm.csic.es.






Figure 1.


oxalyl-type carbonyl moieties and other carbonyl groups at the 4'' position of the 3'-spiro moiety led to compounds **3–10**. Replacement of the labile 5'-TBDMS by other groups gave compounds **11–13**. Finally, for comparative purposes, the *xylo* oxalyl TSAO nucleoside derivative **14** was also prepared.

The stability of compound **2**, in different solvents, was studied by <sup>1</sup>H-NMR experiments. Although compound **2** gets spontaneously desilylated in DMSO-*d*<sub>6</sub> solution on standing in a NMR tube, it was stable in CDCl<sub>3</sub>, CD<sub>3</sub>OD or (CD<sub>3</sub>)<sub>2</sub>CO solutions. Comparative stability studies of compounds **2–14**, in DMSO solution, were also carried out and their conversion into the corresponding 5'-deprotected derivatives in function of time was followed by HPLC. These studies provided the following insights into the hydrolysis (desilylation) reaction:

1. The higher electrophilic character of the 4''-carbonyl the faster the 5'-TBDMS deprotection (**3** > **2** ≫ **4–6**).
2. The desilylation process appears to be also dependent on the nature of the substituent at the oxalyl moiety (**2** ≫ **10** > **9** > **8** > **7**).
3. The rate of desilylation depends on the nature of the silyl group at 5'-position (**2** > **11**).

However, under the same reaction conditions, the 5'-acyl derivative **13** was stable.

A possible mechanism for the desilylation process is outlined in Sch. 1. The proposed mechanism suggests that a direct interaction between the 4''-substituent and the 5'-silyloxy functionalities is critical for the facile desilylation. This was demonstrated when the *xylo* oxalyl ester compound (**14**) was subjected to the same experimental conditions (DMSO) and proved to be stable.



Scheme 1.

Scarce examples of enhanced hydrolytic cleavage of a silyloxy function by neighbouring group participation have been reported.<sup>[3]</sup> Our results complement these previous findings and suggest a generality for this type of process.

### ACKNOWLEDGMENTS

We thank the Spanish CICYT, the Comunidad de Madrid (CAM) and the European Commission (EU) for financial support. The European Commission is also acknowledged for the Descartes 2001 award.

### REFERENCES

1. a) Balzarini, J.; Pérez-Pérez, M.J.; San-Félix, A.; Schols, D.; Perno, C. F.; Vandamme, A. M.; Camarasa, M. J.; De Clercq, E. *Proc. Natl. Acad. Sci. USA*, **1992**, *89*, 4392–4396; b) Rodríguez-Barrios, F.; Pérez, C.; Lobatón, E.; Velázquez, S.; Chamorro, C.; San-Félix, A.; Pérez-Pérez, M. J.; Camarasa, M. J.; Pelemans, H.; Balzarini, J.; Gago, F. J. *Med. Chem.* **2001**, *44*, 1853–1865.
2. Camarasa, M. J.; San-Félix, A.; Pérez-Pérez, M. J.; Velázquez, S.; Alvarez, R.; Chamorro, C.; Jimeno, M. L.; Pérez, C.; Gago, F.; De Clercq, E.; Balzarini, J. *J. Carbohydr. Chem.*, **2000**, *19*, 451–469.
3. a) Kawahara, S.; Wada, T.; Sekine, M. J. *Am. Chem. Soc.*, **1996**, *118* (40), 9461–9468; b) Greco, M.N.; Zhong, H.M.; Marynoff, B.E. *Tetrahedron Lett.* **1998**, *39*, 4959–4962.



